Search

everythinglearnresearchcommunity

for

Search:↓

Riboflavin 5′-phosphate (FMN) shows potential for treating androgen-related conditions but may be limited in treating prostate cancer.

Higher testosterone and DHT levels are linked to hair loss in men, but not to prostate cancer risk.

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.

Trichoscopy helps tell different hair loss types apart using specific scalp and hair patterns.

The conclusion is that individualized treatment and proper medication use are crucial in men's health, with specific recommendations for ED, BPH, and prostate cancer management.

Upadacitinib effectively treated a patient with multiple inflammatory conditions.

A young man with high-grade prostate cancer had successful surgery and good recovery, highlighting the need for awareness in younger men.

Trapa bispinosa Roxb. extract may help reduce prostate size and cell growth in BPH.

Correct testosterone levels for age to treat prostate cancer, using low dose treatments as necessary.

Low testosterone does not prevent prostate cancer in men with type 1 diabetes.

The conclusion is that women are heavily affected by autoimmune skin diseases, face significant challenges, and need better research, treatments, and healthcare policies.

Baldness (androgenic alopecia) could be a risk factor for prostate cancer.

After chemotherapy for early breast cancer, 33.4% of patients had long-term significant hair loss, with some hair regrowth over time, but treatments for hair loss were largely ineffective.

Higher CRP levels suggest chronic inflammation is linked to bladder-related urinary symptoms in men with enlarged prostates.

Early balding may be a sign of future prostate problems.

Patients with metabolic syndrome had lower Gleason scores when diagnosed with prostate cancer.

Finasteride reduces prostate cancer risk but may increase high-grade tumors and has side effects; biopsy methods have similar outcomes; psychosocial factors affect sexual recovery post-surgery.

A higher genetic risk score increases the chance of getting benign prostatic hyperplasia and affects treatment outcomes in Han Chinese men.

Swedish men with the E213 A-allele of the androgen receptor have a lower risk of prostate cancer.

New treatments are making advanced prostate cancer management more complex but also more hopeful.

Larger prostate size in older men may be linked to poorer semen quality and fertility issues.

Dutasteride effectively treats benign prostatic obstruction, improves urinary flow, reduces prostate size, and may prevent prostate cancer, but can cause sexual side effects.

Finasteride is effective for male hair loss, but it may cause fertility issues, mental health problems, and rarely, breast growth. Regular health checks can reduce the risk of prostate cancer. Patient understanding and involvement in treatment is important.

Higher serum androgens contribute to male pattern baldness.

Women with androgenetic alopecia (hair loss) have normal prostate specific antigen levels but higher testosterone levels.

Physalis peruviana extract is more effective in treating benign prostatic hyperplasia in rats than finasteride and terazosine.

There is no link between hair loss and prostate enlargement.

Hair loss is linked to higher prostate-specific antigen levels and urinary symptoms, likely due to age.

Hair loss can be an early sign of prostate enlargement.

Finasteride doesn't harm male fertility or sperm quality, but may slightly reduce ejaculate volume.